Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CKD-702 + irinotecan
- Development stage
- Phase 2
- Lead developer
- Chong Kun Dang Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
CKD-702 + irinotecan is a combination therapy being investigated for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma. This combination specifically targets patients whose tumors overexpress EGFR or MET proteins and is being studied as a third-line or later therapy option. CKD-702 is a tetravalent bispecific antibody that simultaneously targets two important receptors: - Epidermal growth factor receptor (EGFR) - Hepatocyte growth factor receptor (MET) The combination with irinotecan, a topoisomerase inhibitor chemotherapy agent, is being tested to potentially enhance efficacy in treating advanced gastric cancers that have failed previous treatment lines.
02
Targets
TOP1 (DNA Topoisomerase I)EGFR (Epidermal growth factor receptor)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on CKD-702 + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CKD-702 + irinotecan.